Get the Stockscreener App
13.33
0.15%
0.02
After Hours:
13.20
-0.13
-0.98%
Korro Bio Inc stock is traded at $13.33, with a volume of 374.16K.
It is up +0.15% in the last 24 hours and up +68.73% over the past month.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
See More
Previous Close:
$13.31
Open:
$13.12
24h Volume:
374.16K
Relative Volume:
0.79
Market Cap:
$125.53M
Revenue:
-
Net Income/Loss:
$-81.17M
P/E Ratio:
-1.3153
EPS:
-10.1344
Net Cash Flow:
$-82.84M
1W Performance:
+24.23%
1M Performance:
+68.73%
6M Performance:
-18.02%
1Y Performance:
-61.00%
1-Day Range:
$12.87
$13.88
1-Week Range:
$9.88
$14.94
52-Week Range:
$5.2044
$55.89
Korro Bio Inc Stock (KRRO) Company Profile
Name
Korro Bio Inc
Sector
Industry
Phone
617-468-1999
Address
60 FIRST STREET, CAMBRIDGE
Compare KRRO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRRO
Korro Bio Inc
|
13.33 | 125.34M | 0 | -81.17M | -82.84M | -10.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Korro Bio Inc Stock (KRRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-26 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Jan-29-26 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jan-29-26 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-28-26 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Jan-28-26 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-13-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Nov-13-25 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Nov-13-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-13-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-13-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-13-25 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Nov-13-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-29-25 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-16-25 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-21-24 | Initiated | Raymond James | Strong Buy |
| Aug-14-24 | Initiated | William Blair | Outperform |
| Mar-28-24 | Reiterated | H.C. Wainwright | Buy |
| Feb-27-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-04-23 | Initiated | H.C. Wainwright | Buy |
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-10-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-13-23 | Downgrade | Cowen | Outperform → Market Perform |
| Sep-22-21 | Downgrade | Goldman | Buy → Neutral |
| Jan-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-22-20 | Initiated | B. Riley Securities | Buy |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-18-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-28-19 | Initiated | Cowen | Outperform |
| Oct-28-19 | Initiated | Goldman | Buy |
| Oct-28-19 | Initiated | JP Morgan | Overweight |
View All
Korro Bio Inc Stock (KRRO) Latest News
Strength Seen in Korro Bio, Inc. (KRRO): Can Its 13.9% Jump Turn into More Strength? - Nasdaq
Chardan Capital upgrades Korro Bio stock to Buy on KRRO-121 potential By Investing.com - Investing.com Nigeria
Korro Bio's KRRO-121 Receives Strong Analyst Upgrades - Intellectia AI
Korro Bio Shares Rise After Piper Sandler, HC Wainwright Upgrades - marketscreener.com
Korro Bio stock rating upgraded by H.C. Wainwright to Buy on new drug potential - Investing.com
HC Wainwright Upgrades Korro Bio to Buy From Neutral, Price Target is $20 - marketscreener.com
This Fortinet Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Benzinga
HC Wainwright & Co. Upgrades Korro Bio (KRRO) - Nasdaq
KRRO Shares Jump 13% On Analyst UpgradesWhat's Driving The Optimism? - Mena FN
Piper Sandler upgrades Korro Bio stock rating to Overweight on UCD treatment - Investing.com
Chardan Capital upgrades Korro Bio stock to Buy on KRRO-121 potential - Investing.com
Oppenheimer Upgrades Korro Bio (KRRO) - Nasdaq
Korro Bio Shares Rise After Oppenheimer Upgrade - marketscreener.com
Cantor Fitzgerald Upgrades Korro Bio to Overweight From Neutral - marketscreener.com
William Blair reiterates Market Perform rating on Korro Bio stock By Investing.com - Investing.com Canada
Raymond James reiterates Market Perform rating on Korro Bio stock By Investing.com - Investing.com Nigeria
Raymond James reiterates Market Perform rating on Korro Bio stock - Investing.com
Cantor Fitzgerald upgrades Korro Bio stock to Overweight on UCD program - Investing.com
Korro Bio stock holds steady as Jones Trading reiterates Hold rating - Investing.com
Clear Street raises Korro Bio stock price target to $10 on new lead program - Investing.com
Korro Bio Showcases KRRO-121 RNA Editing Program Progress - TipRanks
Korro Bio, Inc. Unveils KRRO-121 as a Potential First-in-Class Treatment - TradingView
Investor Mood: Does Red Rock Resorts Inc have strong fundamentalsJuly 2025 Patterns & Reliable Intraday Trade Alerts - baoquankhu1.vn
Moving Averages: Will Korro Bio Inc benefit from green energy policiesMarket Sentiment Summary & Low Risk High Win Rate Picks - baoquankhu1.vn
Growth Recap: Should I buy Korro Bio Inc stock now2025 Volume Leaders & Safe Capital Growth Stock Tips - baoquankhu1.vn
Korro to Host Virtual Analyst Day on January 27, 2026 - The Manila Times
Parent and liver doctor join Korro Bio to explain ammonia-driven diseases - Stock Titan
FOMO Trade: Should you avoid Korro Bio Inc stock right nowJuly 2025 Price Swings & Verified Momentum Stock Ideas - baoquankhu1.vn
Aug Mood: Is Korro Bio Inc stock a buy or sellPortfolio Gains Report & AI Powered Market Entry Strategies - baoquankhu1.vn
Korro Bio Updates Pipeline, Terminates KRRO-110 REWRITE Trial - TipRanks
Press Release Service: Flashpoint Therapeutics Appoints Venkat R. Krishnamurthy, Ph.D. as Chief Scientific Officer - CRISPR Medicine News
Aug Shorts: Is Advantage Solutions Inc backed by strong institutional buyingMarket Sentiment Review & AI Driven Stock Price Forecasts - baoquankhu1.vn
Korro Bio, Inc. (NASDAQ:KRRO) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Portfolio Shifts: Is Korro Bio Inc. stock positioned for digital transformationTrade Volume Report & Free Long-Term Investment Growth Plans - Bộ Nội Vụ
Korro Bio (NASDAQ:KRRO) Shares Down 5.9% – Here’s What Happened - Defense World
Korro Bio CFO takes medical leave, interim officers appointed - MSN
Will Korro Bio Inc. stock see insider buying2025 Bull vs Bear & Real-Time Price Movement Reports - ulpravda.ru
Inflation Data: Can Korro Bio Inc. stock outperform in 2025 bull marketTrade Analysis Report & Daily Market Momentum Tracking - Улправда
Can Korro Bio Inc. stock outperform in 2025 bull marketWeekly Gains Summary & Long-Term Safe Investment Ideas - Улправда
Market Recap: Can Korro Bio Inc. stock resist market sell offsQuarterly Portfolio Summary & Consistent Profit Alerts - ulpravda.ru
Korro Bio (KRRO) price target decreased by 30.77% to 45.90 - MSN
Is Korro Bio Inc. stock gaining market shareQuarterly Profit Report & Free Community Consensus Stock Picks - Улправда
Will Korro Bio Inc. stock keep outperforming rivalsJuly 2025 Rallies & Free Fast Entry Momentum Trade Alerts - ulpravda.ru
Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewswire Inc.
Aug Analyst Calls: Will Korro Bio Inc stock see insider buyingWeekly Market Outlook & Entry and Exit Point Strategies - Bộ Nội Vụ
Korro Bio enhances executive compensation and retention incentives - MSN
User | times-online.comKorro Bio, Inc.Common Stock (Nasdaq:KRRO) Stock Quote - FinancialContent
Korro Bio, Inc. (NASDAQ:KRRO) Receives Average Rating of “Hold” from Analysts - Defense World
Can Korro Bio Stock Hold Up When Markets Turn? - Trefis
Why analysts remain bullish on Korro Bio Inc. stockIPO Watch & Free Low Drawdown Momentum Trade Ideas - Улправда
Korro Bio Inc Stock (KRRO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):